Lancet Infect Dis by Griffin, Jamie T et al.
Supplementary webappendix
This webappendix formed part of the original submission and has been peer reviewed. 
We post it as supplied by the authors. 
Supplement to: Griffin JT, Bhatt S, Sinka ME, et al. Potential for reduction of burden and 
local elimination of malaria by reducing Plasmodium falciparum malaria transmission: 
a mathematical modelling study. Lancet Infect Dis 2016; published online Jan 19. 
http://dx.doi.org/10.1016/S1473-3099(15)00423-5.
1 
 
The potential for burden reduction and local elimination achievable with reducing 
Plasmodium falciparum transmission: a modelling study.  
Supplementary Information 
JT Griffin1,2 PhD, S Bhatt4 DPhil, ME Sinka4 PhD, PW Gething4 PhD, M Lynch3 MD, E 
Patouillard3,5,6 PhD, E Shutes3 MPH, RD Newman3 MD, Professor P Alonso3 MD, RE 
Cibulskis3 PhD, Professor AC Ghani PhD1* 
1. MRC Centre for Outbreak Analysis & Modelling, Imperial College London 
2. School of Mathematical Sciences, Queen Mary University of London 
3. Global Malaria Programme, WHO 
4. Spatial Ecology and Epidemiology Group, Department of Zoology, University of Oxford 
5. Swiss Tropical and Public Health Institute 
6. Universität Basel 
  
2 
 
The model described here is an extension of a model published in 2010 by Griffin et al.1 and 
subsequently re-fitted to capture the relationship between exposure and clinical disease 2 
and severe disease and death.3 It has been further extended to capture the mosquito 
dynamics as described in White et al.4 The full current model is described in Section 1. The 
model includes multiple malaria interventions. Extensions made to these intervention models 
are detailed in Section 2. Section 3 gives further details of the geographically explicit 
parameters and Section 4 summarises the approach taken to obtain uncertainty intervals. In 
Section 5 we provide links to additional movies showing the changing map of P.falciparum 
malaria under the scenarios outlined in the main manuscript. 
1 P.falciparum transmission model 
The model is described in its deterministic framework here. However, for the simulation 
results modelling multiple interventions, it was implemented as an equivalent stochastic 
individual-based model. The only change to this structure in the stochastic version is the 
non-exponential durations of protection after treatment described in Section 3. 
Susceptible individuals (S) are infected at a rate   which depends on the entomological 
inoculation rate (EIR). After a fixed 12 day latent period, they either develop symptoms (with 
probability  ) or proceed with asymptomatic infection (state A). The probability of 
developing symptoms,  , is determined by an individual’s level of exposure-drive immunity 
(see below) which changes through the course of their lifetime. Those developing disease 
are either successfully treated (entering state T) or fail treatment or are untreated (entering 
state D). Those that are successfully treated subsequently enter a period of prophylaxis (P) 
with the duration of this state depending on the drug used. Following this, individuals return 
to the susceptible state S. Those that fail treatment or are not treated are assumed to self-
resolve and become asymptomatic (entering state A). As only a small proportion of cases 
are fatal (see Section 2) we do not explicitly model deaths in the transmission cycle. 
Individuals with asymptomatic infection subsequently move to a sub-patent state (U) which 
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allows the model to capture onward infection from individuals with low parasite densities. 
Super-infection can occur from states A and U. All states are also stratified by the rate at 
which people are bitten by mosquitoes to capture heterogeneity in exposure.  
The differential equations for the human transmission model are as follows: 
 
/ /
( ) /
(1 ) ( ) /
(1 ) ( ) / /
/ /
/ /
T
T
P U
T
D
D A
UA
T P
S S S
S P d U d
t a
T T T
f S A U T d
t a
D D D
f S A U D d
t a
A A A
S U D d A A d
t a
U U U
A d U d U
t a
P P P
T d P d
t a





 









  
    
  
  
     
  
  
      
  
  
        
  
  
   
  
  
  
  
  
where t  denotes time, a  denotes age and   denotes the biting rate on an individual 
(capturing heterogeneity in exposure). Here Tf  is the proportion of clinical cases receiving 
effective treatment and , , , ,T D A P Ud d d d d  denote the mean duration of states T, D, A, P and 
U respectively. 
Variation in exposure to mosquitoes is included to capture both increased biting with age 
and other sources of heterogeneity in exposure (for example, geographic variation). Each 
individual has a relative biting rate   which is drawn from a Log-Normal distribution with 
parameters 
2
/ 2  and  , such that   has a mean of 1. If 
0 is the mean EIR in adults, 
then the EIR ( ) and force of infection ( ) at age a  are given by the equations:  
 
 0 01 exp( / )a a
b
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where b  is the probability of infection if bitten by an infectious mosquito, and   and 
0a  
determine how the rate of being bitten changes with age. 
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1.1 Acquisition and decay in naturally acquired immunity 
To capture the natural acquisition of immunity to malaria disease and infection, we define 
four empirical functions that apply at different stages of human infection:  
 Pre-erythrocytic immunity, BI : this is assumed to reduce the probability of infection if 
bitten by an infectious mosquito; 
 Acquired and maternal clinical immunity, CAI  and CMI  respectively: the effect of blood 
stage immunity in reducing the probability of developing clinical symptoms; 
 Acquired and maternal immunity to severe disease: Similar quantities VAI  and VMI  
reducing the probability of severe malaria; 
 Detection immunity, DI : the effect of blood stage immunity in reducing the detectability of 
an infection and onward transmission to mosquitoes.  
Each of the four acquired immunity functions are assumed to change with exposure as 
follows, starting from zero at birth: 
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In each equation, , , ,VA,Dku k B CA  limits the rate at which immunity can be boosted 
at high exposure and each , , , ,kd k B C V D  determines the duration of immunity.  
The immunity functions are transformed by Hill functions to give the probabilities of each 
transition affected by immunity. The probability of infection decreases from 0b  with no 
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immunity to a minimum of 
0 1b b , and is given by the following formula where 0BI  and B  are 
scale and shape parameters respectively: 
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At birth, maternal clinical immunity CMI  is MP  times the acquired immunity of a 20 year-old, 
then decays at rate 1/ Md . The probability of clinical disease is 0  with no immunity, and 
has a minimum of 0 1  , and is given by the following formula where 0CI  and C  are scale 
and shape parameters respectively: 
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The probability of severe malaria if newly infected is similar, apart from an extra age-
dependent term Vf : 
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where  01 (1 ) / 1 ( / ) VV V Vf f a a      at age a , with parameters 0Vf , Va  and V .
 
The probability of detecting an asymptomatic infection by microscopy is 
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mind  is the minimum probability, 0D
I  and D  are scale and shape parameters, and 
 01 (1 ) / 1 ( / ) DD D Df f a a      at age a , with parameters 0Df , Da  and D .  
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This reduced detectability is assumed to result from a lower parasite density, which also 
reduces the probability of infecting a mosquito if bitten. In states D  and U , infectiousness is 
Dc  and U
c
 
respectively. Following treatment, infectivity is Tc . In state A , infectiousness is 
( ) IU D Uc c c q
   where q  is the probability of detection of parasites.  
The estimates of the central human transmission model parameters and their 95% credible 
intervals where fitted are given in Table S1. Full details and estimates of the parameters 
governing immunity are given in Griffin et al. 2014 and 2015.5,6 
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Table S1: Parameters for the baseline human transmission model.  
Parameter Symbol Estimate (95% credible interval) 
Human infection duration (days) 
Latent period 
Ed  
12 (fixed) 
Patent infection 
Id  
200 (fixed) 
Clinical disease (treated) 
Td  
5 (fixed) 
Clinical disease (untreated) 
Dd  
5 (fixed) 
Sub-patent infection  
Ud  
110 (87,131) 
Prophylaxis following treatment 
Pd  
Based on drug PK/PD profile7 
Infectiousness to mosquitoes 
Lag from parasites to infectious 
gametocytes 
lt  
12.5 days (fixed) 
Untreated disease 
Dc  
0.068 day-1(0.039, 0.122) 
Treated disease 
Tc  
Drug-dependent 
Sub-patent infection 
Uc  
0.0062 day-1 (0.00056, 0.018) 
Parameter for infectiousness of 
asymptomatic state 
I  
1.82 (0.603, 8.54) 
Age and heterogeneity 
Age-dependent biting parameter   0.85 (fixed) 
Age-dependent biting parameter 
0a  
8 years (fixed) 
Variance of the log heterogeneity in biting 
rates 
2  1.67 (fixed) 
Parameters determining immunity 
Probability that an infectious bite leads to 
infection  
b   See Griffin et al. (2014) and 
(2015) for further details5,6 
Probability that an infection leads to 
disease 
  
Probability that an infection leads to 
severe disease 
   
Probability that an infection will be 
detected 
q   
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1.2 Mortality 
The model has previously been fitted to data on the incidence of severe malaria in different 
transmission settings as described in Griffin et al.6. This allows us to estimate the relative 
incidence and changing age distribution of severe malaria as transmission intensity varies 
from a wide range of African datasets and also obtain estimates of the case fatality in 
hospital using data from Tanzania. However there remains considerable uncertainty in the 
overall incidence of severe malaria (including those who do not reach hospital), and 
consequently in the case fatality of severe cases who do not reach hospital. To obtain an 
estimate of the overall mortality rate we therefore used data collated by Rowe et al.8. In that 
study, verbal autopsy data were used to estimate the relationship between reported 
estimates of parasite prevalence in children and mortality due to malaria in under-fives from 
the same location. The data were collected in the late 1980s and 1990s, prior to the 
widespread scale-up of intervention coverage.  
The model described above predicts the incidence of hospitalised severe malaria at time t  
and age a , ( , ) ( , , ) ( , )dH a t a t a t

     , where   is the force of infection,   is the 
proportion of new infections that result in severe malaria and   is the heterogeneity in 
exposure. We assume that the overall mortality due to malaria ( , )a t  is proportional to the 
incidence of hospitalised severe malaria: 
 ( , ) ( , )Ha t a t   
To estimate the scaling factor   using the verbal autopsy data, we ran our simulation model 
with no long-lasting insecticide treated nets (LLINs) and the constant assumed treatment 
rate for each first administrative unit in Africa, and output the parasite prevalence in 2 to 10 
year olds and hospitalised severe malaria incidence in under-fives. We then estimated   by 
least squares, weighted by the population in each first administrative unit. The resulting 
estimate when using the best-fit transmission model parameters  in Table S1 is that we 
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multiply the model-predicted incidence of hospitalised severe malaria in a given age group 
by  = 0.215 to predict overall mortality due to malaria in the same age group. We re-
estimated   for each set of transmission model parameters when carrying out the 
uncertainty analysis described below. 
When coverage of effective treatment is scaled up, this is likely to reduce the probability of 
progressing to severe malaria and death. We assume that effective treatment for 
uncomplicated malaria prevents a proportion   of deaths. As there are no reliable data for 
this parameter, we sampled a value uniformly between 0 and 1. Suppose that the proportion 
of uncomplicated malaria cases that are effectively treated was historically 0f  and is now 1f . 
Then the incidence of severe malaria and mortality due to malaria are both multiplied by 
1 1
0 0
(1 ) (1 )
(1 ) (1 )
f f
f f


  
  
  
relative to the incidence if treatment coverage remained at 0f . 
1.3 Mosquito dynamics 
The full lifecycle of the mosquito is modelled in a compartmental formulation9. Female adult 
mosquitoes (M) lay eggs at rate   which then develop through the early and late larval 
stages (E and L) to the pupal stage (PL). The death rate of the larval stages is increased by 
a density-dependent factor. Pupae emerge as adult mosquitoes, with 50% being female, 
which are susceptible to infection (SM). The differential equations are:  
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where each   is a death rate, each d  is the duration in a state, and   modifies the effect of 
density dependence on late stage relative to early stage larvae. K  is the time-varying 
carrying capacity, the ability of the environment to support mosquito larvae, which 
determines the mosquito density and hence the baseline transmission intensity in the 
absence of interventions.  
Adult mosquitoes become infected at a rate which depends on the infectiousness of the 
human population, which in turn depends on the infection states at time 
lt  previously, where 
lt  represents the time lag in humans from asexual parasites to onward infectiousness. The 
force of infection on mosquitoes is the sum of the contributions from the different human 
infection states: 
 
0 0
( ) ( , , ) ( , , ) ( , , ) ( , , )M D l T l A l U la c D a t t c T a t t c A a t t c U a t t da d
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The biting rate on humans is 0 /Q  , where   is the mean time between feeds and 0Q  
is the proportion of bites that are on humans (anthropophagy).
0
( ) ( )a g a da 

   is a 
normalizing constant for the biting rate over ages, where ( )g a  is the cross-sectional human 
age distribution.  
Once infected, mosquitoes pass through a latent period (EM) of fixed length M  and then 
they become infectious to humans (IM). They are assumed to remain infectious until they die. 
The infection process in the mosquito population is as follows: 
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where 
M  is the death rate and 
M M
MP e
   is the probability that a mosquito survives the 
extrinsic incubation period. The mean EIR for adult humans is then given by  
0 /MI    
The parameter values for the mosquito population model are given in  
 
Table S2.  
 
Table S2: Parameters for the mosquito population model.  
Parameter Symbol Estimate 
Daily mortality of adults 
M  
Varies by species 
Per capita daily mortality rate of early 
stage larvae (low density) 
E  
0.034 day-1 
Per capita daily mortality rate of late 
stage larvae (low density) 
L  
0.035 day-1 
Per capita daily mortality rate of 
pupae 
P  
0.25 day-1 
Mean time between bites in humans   3 days 
Development time of early stage 
larvae 
ELd  
6.64 days 
Development time of late stage larvae 
Ld  
3.72 days 
Development time of pupae 
PLd  
0.64 days 
Number of eggs laid per day per 
mosquito 

 
21.19 day-1 
Relative effect of density dependence 
on late instars relative to early instars 
  13.25 
Extrinsic incubation period 
M  
10 days 
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2 Intervention Models 
2.1 Treatment for uncomplicated and severe malaria 
When used as treatment for uncomplicated malaria, we assume that non-ACTs have a 75% 
probability of being effective in clearing an infection, whereas ACTs have a 95% probability 
of being effective.1 If a drug is effective, then it also provides a period of prophylaxis with a 
profile of protection over time that differs for each drug, and also varies by age, as estimated 
for artemether/lumefantrine (AL) and DHA-piperaquine by Okell at al.7 We assumed that 
ACTs have the properties of AL, and for non-ACTs, we assumed a 30 day duration of 
prophylaxis.10 
Rectal artesunate given in the community was assumed to reduce progression to severe 
malaria by 50%.11 Injectable artesunate as a treatment for severe malaria in hospital has a 
23% efficacy in reducing mortality in under-fives and 35% efficacy in over fives compared to 
treatment with quinine12,13 which is assumed to be the standard treatment in hospital before 
injectable artesunate is introduced.  
2.2 Seasonal Malaria Chemoprevention 
Seasonal malaria chemoprevention (SMC) consists of three courses of treatment (SP plus 
amodiaquine) during the transmission season. Treatment courses were given to the target 
population at the peak of the transmission season (as defined by the peak of the carrying 
capacity ( )K t ), and one month before and after the peak. We assumed that the drug was 
efficacious and provided a period of prophylaxis of approximately 30 days. SMC was 
implemented in sufficiently seasonal areas of sub-Saharan Africa, defined as areas with at 
least 60% of the rainfall occurring in the peak three months of the year, and where the 
incidence of clinical malaria in under-fives was at least 0.1 cases per person per year at 
baseline.14 In the first and second acceleration scenarios, SMC was only implemented in the 
Sahel, as there is wide-spread resistance to sulfadoxine/pyrimethamine (SP) in East Africa. 
In the innovate scenario, SMC was also implemented in suitable areas of Africa outside the 
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Sahel, under the assumption that a drug combination would be available that could be used 
for SMC where there is currently SP resistance.  
2.3 Vector Control 
LLINs and IRS are modelled as described in Griffin et al. (2010)1 apart from one change to 
the intervention model structure, which was that now we allow the possibility that IRS kills a 
mosquito as it rests in a house before feeding. Both interventions are modelled by 
calculating the probabilities that a mosquito trying to feed is killed, repelled or successfully 
feeds. These probabilities were based on an updated literature review of experimental hut 
studies (manuscript in preparation), and are listed in Table S3. The endophily parameters for 
Anopheles gambiae ss, arabiensis and funestus in Table S5 were also based on this 
updated review. 
Table S3: Parameters for the effects of LLINs and IRS 
 Probability of being: Symbol Value 
LLINs 
Repelled before entering 
house E
r
  0.113 
 Repelled by net Pr  0.295 
 Killed by net Nd  0.533 
IRS 
Repelled before entering 
house I
r
 0.687 
 Killed before feeding IWd  0.295 
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3 Country-specific Parameters 
3.1 Vector species and behaviour 
For each country, we identified the three most important dominant vector species. Within 
Africa, we used a published model based on rainfall and humidity to estimate the relative 
density of two of the dominant species (An.gambiae s.s. and An.arabiensis).15 In areas 
where the third dominant species (An.funestus) is also present, we assumed that this 
represented 20% of the total vector population. This assumption has relatively little impact 
on the outcomes as the effectiveness of LLINs and IRS is most impacted by the density of 
An.arabiensis. 
Outside Africa, the dominant vector species were taken from estimates of their 
presence/absence.16-19 Up to three dominant species were identified in each country, and 
then the proportions that each species represent out of the total mosquito numbers were 
given the values in Table S4, dependent on how many dominant species there were. 
Table S4: Parameters assumed for the relative density of the three dominant vector 
species in each country 
 Relative proportion of each species 
 Species 1 Species 2 Species 3 
Three dominant 
species 
0.6 0.3 0.2 
Two dominant 
species 
0.6 0.4 - 
One dominant 
species 
1 - - 
 
The parameters for vector behaviour that determine the impact of LLINs and IRS are shown 
in Table S5. The quantity of data on these traits varies by species and for many is not 
available. Hence we took two different approaches inside and outside Africa. For the three 
dominant species in Africa we used estimates for each of these traits (apart from endophily) 
from the literature, as in our previous work.1 For each species outside Africa we first 
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calculated the proportion of papers that reported each species to have any of these four 
traits based on the information published in the bionomics references.16-19 Next, we used a 
threshold to turn these reports into binary outcomes – high and low – for each trait. This 
threshold was set at a level which best represented the overall split in the data for each trait 
(close to 50% for the first 3 traits and 75% for the last trait). Finally, we assigned fixed 
numerical values for each trait for a high/low level, based on data from An.gambiae s.s (high 
anthropophagy, endophily, endophagy and proportion of bites indoors when people are in 
bed) and An.arabiensis (low anthropophagy and endophily), but less endophagic than 
An.arabiensis.  
Table S5: Bionomics of the categorised vector species 
Trait An.gambiae 
s.s 
An.arabiensi
s 
An.funestus “High” “Low” 
Anthropophagy 0.92 0.71 0.94 0.9 0.6 
Endophily 0.813 0.422 0.813 0.85 0.3 
% bites indoors  0.97 0.96 0.98 0.96 0.6 
% bites indoors and 
in bed 
0.89 0.9 0.9 0.9 0.5 
 
3.2 Demographic and parasite prevalence data 
The total population in each country by year and the changing age distribution were based 
on the UN World Population Projections, which consist of data up to 2012, and projections 
from 2013 onwards.20 The data included estimates of the population by 5-year age-groups, 
infant mortality, and the birth rate per person. Annual population data were available, 
whereas yearly infant mortality and birth rates were interpolated from five-yearly data. 
Population growth was considered separately for urban and rural areas, as these differ due 
to trends in urbanisation. Estimates of the population spatial distribution in 2010 within each 
country at a resolution of 1km2 were taken from GRUMP.21 As the country totals for these 
population estimates do not necessarily match the UN data perfectly, the populations were 
first rescaled so that the total in each country matched the UN 2010 data.  
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The baseline transmission intensity is based on estimates of parasite prevalence in 2 to 10 
year olds in 2010 from the Malaria Atlas Project (MAP).22 These estimates were made based 
on data from 22,212 P.falciparum parasite rate surveys.  We combined these data with the 
demographic data to calculate, for each first administrative unit, the mean P. falciparum 
parasite prevalence weighted by population, and the total population and the population 
living in areas with stable transmission of P. falciparum (referred to in the main text as the 
population at risk). The calculations were undertaken separately for urban and rural areas.  
For calculation of incidence of cases and deaths, the denominator population was taken as 
the total population in first administrative areas which were malaria-endemic in 2010. The 
growth in the population of these areas over the period 2015 to 2030 is projected to be 25% 
overall, with 44% growth in Africa, 15% in Asia and the Pacific, and 15% in Latin America. 
The projected growth in urban populations is 71%, 40% and 22% respectively, whereas the 
growth in rural populations is 27%, 2% and -4%.  
In the main text we report changes in case incidence and mortality. These are per population 
statistics and hence are not influenced by population growth. We also report absolute 
numbers of cases and deaths averted as these statistics are commonly used in reporting. It 
should be noted that these numbers do capture the substantial population growth outlined 
above.  
3.3 Calibration of baseline transmission intensity 
The carrying capacity of the environment to support mosquito larvae, ( )K t , is assumed to 
be proportional to rainfall. A seasonal curve was estimated from daily rainfall data from 2002 
to 2009 using the first three frequencies of the Fourier-transformed data as detailed in 
Garske et al.23, and the results were aggregated to the first administrative units. Let ( )R t  be 
this rainfall curve, with mean over the year of R . To calibrate the model to match the MAP 
2010 parasite prevalence data, we repeatedly ran the deterministic transmission model over 
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50 years up to 2010 within a root-finding algorithm, using the site-specific data on vectors, 
LLIN scale-up and treatment for clinical malaria. The seasonal carrying capacity is taken as 
0( ) ( ) /K t K R t R  
with 0K  varying at each iteration of the root-finding procedure until a value of 0K  which 
gives the desired prevalence in 2010 is found. This calibration was done separately for 
urban and rural populations in each first administrative area. We assumed that apart from 
seasonal variation, ( )K t  remains constant over time, so that with a growing human 
population, in the absence of interventions, the mosquito density per person decreases. 
Outside Africa, and in Botswana, Namibia, South Africa and Madagascar, there was an 
additional calibration step, rescaling all values of 0K  within each country (by a single factor 
per country) so that the number of clinical malaria cases in 2010 matched the number 
estimated by the WHO, as summarised in the 2013 World Malaria Report (WMR).24 In these 
countries, we assumed that the minimum incidence of clinical malaria in 2010 among the at-
risk population was 1 case per 100 people per year. To achieve this, where necessary we 
decreased the population at risk from that derived from the MAP and demographic data, 
while still matching the total number of cases in each countries as estimated by the WHO. 
3.4 Coverage of interventions from 2000 to 2015  
3.4.1 LLIN Coverage 
For LLINs we define coverage as usage of nets, as measured frequently in DHS/MIS 
surveys. LLIN usage in sub-Saharan Africa was estimated from a model which was jointly 
fitted to data on numbers of nets delivered to countries and data from household surveys of 
ownership and use of LLINs.25 The model provides estimates of the proportion of the 
population who sleep under an LLIN in each country by year from 2000 to 2013. Outside 
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Africa we used National Malaria Control Program reports of LLIN usage collated by 
WHO/GMP from 2000 to 2012 and reported for recent years in the WMR 2013.  
In our simulation model, we assume that nets are distributed every three years to up to one 
third of the population (all-age to reflect the policy of universal coverage), and that after 
people receive a new net, usage falls at a constant rate with a mean duration of usage of 5 
years. For each country, we numerically found the set of annual distribution coverages that, 
with our simulation assumptions, most closely match the usage estimates, by minimising the 
sum of squares of the difference between the annual usages output from our simulation and 
the annual usages from the distribution/ownership model or WHO data. 
For the “Sustain” scenario the LLIN usage, weighted by population of malaria-endemic 
areas, has a median value of 42% (interquartile range 6-60%). The other scenarios have a 
target access level, where usage is 88% of access as estimated in Bhatt et al. 25 
3.4.2 IRS Coverage 
For IRS we define coverage as the proportion of people residing in a house that has been 
sprayed within the past 12 months. Data on IRS coverage by country was taken from the 
WMR 2013 which collates coverage reported from the National Malaria Control 
Programmes. For the “Sustain” scenario the LLIN coverage, weighted by population of 
malaria-endemic areas, has a median value of 11% (interquartile range 1-19%). IRS 
coverage is not continued in scenarios two, three and four since we model vector control via 
LLINs only.  
3.4.3 SMC Coverage 
For SMC we define coverage as the proportion of children residing in an area suitable for 
SMC that receive the full 3 courses of SP-amodiaquine. We do not model partial adherence 
to this schedule.  SMC is not included in the “Sustain” scenario. 
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3.4.4 Treatment Coverage 
For first-line treatment for uncomplicated malaria (clinical disease) we define coverage as 
the proportion of those that develop disease that receive a full course of an appropriate and 
efficacious drug (either non-ACT or ACT – see section 2.1. This coverage figure therefore 
encompasses treatment seeking, appropriate diagnosis, the availability of ACTs and 
adherence to the dosing schedule. The complexities of this treatment seeking pathway are 
not explicitly modelled here given the wide variation within and between countries. Instead 
this is reflected in country-specific coverage estimates. 
In Africa, antimalarial and ACT coverage (i.e. the proportion receiving either a non-ACT or 
ACT) plus the proportion of these treatments received in the public versus private sector 
were based on modelled estimates from DHS and MICS surveys reported in Cohen et al. 26. 
Outside Africa we used data from the WMR 2013 which is reported by the National Malaria 
Control Programmes. The latter coverage levels reflect treatment in the public sector only. In 
the absence of further data we therefore assumed that coverage levels would be 50% lower 
in the private sector compared to the public sector. Data on the proportion of cases seeking 
care in the public and private sectors was obtained from the WMR 2013 as reported by 
National Malaria Control Programmes.  
For the “Sustain” scenario the first-line treatment coverage, weighted by population of 
malaria-endemic areas, has a median value of 36% (interquartile range 31-40%). 
Data on case management rates for severe disease (i.e. the proportion of severe disease 
cases that receive hospital care) are limited. For a given transmission setting, we previously 
estimated severe malaria incidence in hospital H   and incidence of mortality due to malaria, 
H  , with  estimated as described in section 1.2. We also have an estimate of the case 
fatality of hospitalised severe malaria, Hm  of 0.065, based on the study of Reyburn et al.
27 
To estimate the overall incidence of severe malaria, we took the case fatality outside hospital 
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Cm  to be 0.6, based on the review by Lubell at al.
28 Then to reconcile these estimates, the 
incidence of non-hospitalised severe malaria C  must satisfy 
( )
H H C C H
H
C H
C
m m
m
m
   

 
  


 
In scenarios three and four, rectal artesunate in the community reduces Cm  
, and in 
scenarios two, three and four, injectable artesunate in hospital reduces Hm .   
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4 Simulations and Uncertainty Analysis 
 
Simulations were run separately in urban and rural populations in each first administrative 
unit, with no spatial linking of transmission between them. The size of the simulated 
populations ranged from 12,000 for the places with highest transmission to 60,000 at low 
transmission. Each simulation was run for 50 years prior to 2015.  
When we fitted the transmission model to data as described in 5,6, we used a Bayesian 
framework, thus obtaining a posterior distribution of parameter sets. From these, we chose 
50 sets of parameters at random. For each set of parameters, we repeated the calibration of 
the baseline transmission intensity in each country and first administrative unit. Uncertainty 
in the vector bionomics was included by sampling each of the parameters listed in Table S5 
from a Logit Normal distribution with median equal to the value in the table and standard 
deviation on the logit scale of 0.4 in Africa and 0.8 outside Africa. For each of the 50 
parameter sets, we also repeated the rescaling to the mortality data estimated by verbal 
autopsy and sampled the rescaling parameter   from a gamma distribution with mean equal 
to the fitted value and standard deviation equal to the standard error from the fitting of  .  
We then ran each simulation scenario for all 50 sets of parameters. For each result in the 
main text, the point estimate is the mean over the 50 simulation runs, after aggregating over 
countries, and over years where necessary. Approximate 95% credible intervals were 
calculated by fitting a three parameter distribution to the outputs from the 50 simulations 
using maximum likelihood, and calculating the 2.5th and 97.5th percentiles of the fitted 
distribution. The distributions chosen were a generalised gamma distribution for outcomes 
that must be non-negative, such as the number of cases or deaths, and a skew-normal 
distribution for outcomes that could be positive or negative, such as the relative or absolute 
change in cases or deaths. 
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5 Additional explanation of rebounds 
 
As shown in Figure 1 of the main text, under the “sustain” scenario in which coverage of 
interventions remains at 2013 level, we predict a small rebound in case incidence and 
mortality. This is due to a reduction in the rate of acquisition of immunity in younger children 
that are exposed at a lower level and hence a shifting in cases to older ages. As we 
demonstrate here, this is not unique to malaria but is the expected outcome of any 
intervention that reduces the hazard of infection and hence results in a later age at first (and 
subsequent) infections. 
To illustrate this, we use a very simple example of multiple birth cohorts experiencing a fully-
immunising infection. Assume that each child experiences a constant risk of infection from 
2000 to 2009 which then decreases to a lower level from 2010 onwards, as illustrated in 
Figure S1. All children are assumed to survive throughout. 
Figure S1: Scenario with a reduced risk of infection from 2009 onwards.   
 
To further simplify, assume that the infection always results in disease and that the child is 
then fully immune following this single infection. Figure S2 shows the cumulative probability 
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of having been infected by age in four cohorts of children. In those born in the year 2000, the 
high risk of infection means that the majority are infected early in life with almost all having 
experienced infection by the age of 5. A similar pattern is observed for those born in 2005. 
However, now we see a flattening of the curve from age 4 onwards as those that have not 
been infected by 2009 (the year in which transmission decreases) acquire infection at a 
slower rate. Of those born in 2008 a large proportion are infected in their first year of life, but 
after this the rate of acquisition of infection is slower, reflecting the reduced risk of infection 
from 2009 onwards. Finally, the 2010 and all later cohorts acquire infection at a slower rate 
as they are exposed only to the lower risk of infection throughout their life.  
Figure S2: The cumulative probability of acquiring infection by age for four different cohorts.  
 
The reduction in infection risk from 2009 therefore results in an increase in the average age 
of first infection for the later cohorts compared with the baseline situation (represented by the 
2005 cohort). This effect explains the increase in age of cases that has been observed in 
many malaria endemic settings as transmission declines.  
In addition, Figure S2 shows how the probability of acquiring infection by age 10 decreases 
in each cohort, representing an absolute reduction in risk over an individual’s lifetime. This is 
further illustrated in Figure S3, which shows the age distribution of the cases by cohort.  
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Figure 3: Age distribution of cases in children under 5 years by cohort. The later cohorts experience a 
lower risk of infection and hence cases are shifted to older ages.  
 
Figure S4 shows how the same data in Figure S3 can be re-plotted with calendar year along 
the x-axis to demonstrate the contribution of the different cohorts to overall case incidence in 
children under 5 years of age. In each bar, the top segment represents 0 year olds, the 
second bar 1 year olds, the third 2 year olds etc.  In 2007 and 2008 the proportion of cases 
in each age-group is constant. Following the 2009 decrease in infection risk, the case 
incidence in the 0 year olds (2009 cohort) is smaller than that in 2007/2008. Notably, the 
number of cases occurring in 2009 in the 2007 and 2008 cohorts (navy and dark blue 
respectively) is low as most of the children in these cohorts have experienced their infection. 
As the new cohorts emerge, children experience their infection at older ages and so these 
new cases give rise to an increase in the overall case incidence. However the total risk of 
infection in the later cohorts is always lower than in the earlier cohorts. 
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Figure S4: (A) Contribution of cohorts to the total case incidence in children under 5 years of age. The 
colours denote the cohorts of children born from 2003 to 2015. (B) Summary trajectory of case incidence 
in children under 5 years of age. 
(A) (B) 
  
 
6 Additional Maps and Movies 
The following movies show the yearly output of the model from 2010 to 2030. 
Movie S1: Changing map of P.falciparum under the Sustain scenario.  
Movie S2: Changing map of P.falciparum under the Accelerate 1 scenario.  
Movie S3: Changing map of P.falciparum under the Accelerate 2 scenario.  
Movie S4: Changing map of P.falciparum under the Innovate scenario.  
Movie S5: Changing map of P.falciparum under the Reverse scenario.  
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